Skip to main content
Top
Published in: Clinical and Translational Oncology 11/2005

01-12-2005 | Original Articles

A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)

Authors: Joan Maurel Santasusana, José Luis García López, Juan José Bretón García, Ana Isabel León Carbonero, Javier Gallego Plazas, Pedro Sánchez Rovira, Carlos Fernández Martos, Ma Carmen Galán Guzmán, Jesús Florián Jericó, Francisco Javier Dorta Delgado, Javier Casinello Espinosa, Marta Llanos Muñoz, Enrique Aranda Aguilar, Javier Sastre Valera, Ignacio García Ribas, Alfredo Carrato Mena

Published in: Clinical and Translational Oncology | Issue 11/2005

Login to get access
Metadata
Title
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)
Authors
Joan Maurel Santasusana
José Luis García López
Juan José Bretón García
Ana Isabel León Carbonero
Javier Gallego Plazas
Pedro Sánchez Rovira
Carlos Fernández Martos
Ma Carmen Galán Guzmán
Jesús Florián Jericó
Francisco Javier Dorta Delgado
Javier Casinello Espinosa
Marta Llanos Muñoz
Enrique Aranda Aguilar
Javier Sastre Valera
Ignacio García Ribas
Alfredo Carrato Mena
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 11/2005
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02717002

Other articles of this Issue 11/2005

Clinical and Translational Oncology 11/2005 Go to the issue

News

News

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine